StreetInsider.com News Articles

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

Sat, 30 May 2026 14:30:00 -0400

SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC

SEZ6 expression is positively correlated with DLL3 expression across neuroendocrine carcinomas, indicating potential for combination

Findings support Whitehawk's development of SEZ6-directed ADC, HWK-206, with an IND submission expected mid-2026

MORRISTOWN, N.J., May 30, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced the presentation of a real world analysis supporting the therapeutic potential of targeting seizure

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

Sat, 30 May 2026 14:30:00 -0400

SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC

SEZ6 expression is positively correlated with DLL3 expression across neuroendocrine carcinomas, indicating potential for combination

Findings support Whitehawk's development of SEZ6-directed ADC, HWK-206, with an IND submission expected mid-2026

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

Sat, 30 May 2026 14:30:00 -0400

SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC

SEZ6 expression is positively correlated with DLL3 expression across neuroendocrine carcinomas, indicating potential for combination

Findings support Whitehawk's development of SEZ6-directed ADC, HWK-206, with an IND submission expected mid-2026

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

Sat, 30 May 2026 14:30:00 -0400

SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC

SEZ6 expression is positively correlated with DLL3 expression across neuroendocrine carcinomas, indicating potential for combination

Findings support Whitehawk's development of SEZ6-directed ADC, HWK-206, with an IND submission expected mid-2026

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

Sat, 30 May 2026 14:30:00 -0400

SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC

SEZ6 expression is positively correlated with DLL3 expression across neuroendocrine carcinomas, indicating potential for combination

Findings support Whitehawk's development of SEZ6-directed ADC, HWK-206, with an IND submission expected mid-2026

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

Sat, 30 May 2026 14:30:00 -0400

SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC

SEZ6 expression is positively correlated with DLL3 expression across neuroendocrine carcinomas, indicating potential for combination

Findings support Whitehawk's development of SEZ6-directed ADC, HWK-206, with an IND submission expected mid-2026

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

Sat, 30 May 2026 14:30:00 -0400

SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC

SEZ6 expression is positively correlated with DLL3 expression across neuroendocrine carcinomas, indicating potential for combination

Findings support Whitehawk's development of SEZ6-directed ADC, HWK-206, with an IND submission expected mid-2026

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

Sat, 30 May 2026 14:30:00 -0400

SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC

SEZ6 expression is positively correlated with DLL3 expression across neuroendocrine carcinomas, indicating potential for combination

Findings support Whitehawk's development of SEZ6-directed ADC, HWK-206, with an IND submission expected mid-2026

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

Sat, 30 May 2026 14:30:00 -0400

SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC

SEZ6 expression is positively correlated with DLL3 expression across neuroendocrine carcinomas, indicating potential for combination

Findings support Whitehawk's development of SEZ6-directed ADC, HWK-206, with an IND submission expected mid-2026

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

Sat, 30 May 2026 14:30:00 -0400

SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC

SEZ6 expression is positively correlated with DLL3 expression across neuroendocrine carcinomas, indicating potential for combination

Findings support Whitehawk's development of SEZ6-directed ADC, HWK-206, with an IND submission expected mid-2026

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

Sat, 30 May 2026 14:30:00 -0400

SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC

SEZ6 expression is positively correlated with DLL3 expression across neuroendocrine carcinomas, indicating potential for combination

Findings support Whitehawk's development of SEZ6-directed ADC, HWK-206, with an IND submission expected mid-2026

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

Sat, 30 May 2026 14:30:00 -0400

SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC

SEZ6 expression is positively correlated with DLL3 expression across neuroendocrine carcinomas, indicating potential for combination

Findings support Whitehawk's development of SEZ6-directed ADC, HWK-206, with an IND submission expected mid-2026

Form S-3 Whitehawk Therapeutics,

Fri, 29 May 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260529/26575454.html

Form S-3 Whitehawk Therapeutics,

Fri, 29 May 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260529/26575454.html

Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference

Thu, 28 May 2026 16:05:00 -0400

MORRISTOWN, N.J., May 28, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced Dave Lennon, PhD, President and CEO, will present at the Jefferies 2026 Global Healthcare Conference in New York City, NY on Thursday, June 4 at 8:10 AM ET.

A live webcast of the fireside chat can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event.

About

Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference

Thu, 28 May 2026 16:05:00 -0400

MORRISTOWN, N.J., May 28, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced Dave Lennon, PhD, President and CEO, will present at the Jefferies 2026 Global Healthcare Conference in New York City, NY on Thursday, June 4 at 8:10 AM ET.
A live webcast of the fireside chat can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event.
About

Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference

Thu, 28 May 2026 16:05:00 -0400

MORRISTOWN, N.J., May 28, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced Dave Lennon, PhD, President and CEO, will present at the Jefferies 2026 Global Healthcare Conference in New York City, NY on Thursday, June 4 at 8:10 AM ET.
A live webcast of the fireside chat can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event.
About

Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference

Thu, 28 May 2026 16:05:00 -0400

MORRISTOWN, N.J., May 28, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced Dave Lennon, PhD, President and CEO, will present at the Jefferies 2026 Global Healthcare Conference in New York City, NY on Thursday, June 4 at 8:10 AM ET.
A live webcast of the fireside chat can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event.
About

Form 8-K Whitehawk Therapeutics, For: May 21

Thu, 21 May 2026 17:16:00 -0400
si-local-file:///var/storage/secattach/20260521/26536865.html

Form 8-K Whitehawk Therapeutics, For: May 21

Thu, 21 May 2026 17:16:00 -0400
si-local-file:///var/storage/secattach/20260521/26536865.html

Whitehawk Therapeutics signs option deal for up to five new ADC programs

Thu, 21 May 2026 17:05:39 -0400

Whitehawk Therapeutics Inc. (NASDAQ: WHWK) entered into an option agreement with Hangzhou DAC for access to CPT113 linker-payload technology to develop up to five additional antibody drug conjugate programs.
Under the agreement terms, Whitehawk will select targets and source antibodies while retaining global rights and full program control for the new ADC programs. The company anticipates submitting Investigational New Drug applications for multiple new programs over the next 12-24 months.
Whitehawk's ADC platform combines CPT113 as the core linker-payload technology with its proprietary Carbon Bridge Cysteine Re-pairing bioconjugation process. The company states this approach supports improved stability and therapeutic index compared to

Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload

Thu, 21 May 2026 17:05:00 -0400

Agreement with Hangzhou DAC Provides Option for Up to Five New, Internally Developed ADC Programs, Including Dual-Payload Variations
Hangzhou DAC's DXC006 Data at ASCO Reinforce Conviction for CPT113, a Core Technology of Whitehawk's ADC Platform
Phase 1 Dose-Escalation Trials of HWK-007 and HWK-016 are Currently Enrolling; HWK-007 Trials-in-Progress Poster to be Presented at ASCO
MORRISTOWN, N.J., May 21, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced it entered into

Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload

Thu, 21 May 2026 17:05:00 -0400

Agreement with Hangzhou DAC Provides Option for Up to Five New, Internally Developed ADC Programs, Including Dual-Payload Variations
Hangzhou DAC's DXC006 Data at ASCO Reinforce Conviction for CPT113, a Core Technology of Whitehawk's ADC Platform
Phase 1 Dose-Escalation Trials of HWK-007 and HWK-016 are Currently Enrolling; HWK-007 Trials-in-Progress Poster to be Presented at ASCO
MORRISTOWN, N.J., May 21, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced it entered into

Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload

Thu, 21 May 2026 17:05:00 -0400

Agreement with Hangzhou DAC Provides Option for Up to Five New, Internally Developed ADC Programs, Including Dual-Payload Variations
Hangzhou DAC's DXC006 Data at ASCO Reinforce Conviction for CPT113, a Core Technology of Whitehawk's ADC Platform
Phase 1 Dose-Escalation Trials of HWK-007 and HWK-016 are Currently Enrolling; HWK-007 Trials-in-Progress Poster to be Presented at ASCO
MORRISTOWN, N.J., May 21, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced it entered into

Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload

Thu, 21 May 2026 17:05:00 -0400

Agreement with Hangzhou DAC Provides Option for Up to Five New, Internally Developed ADC Programs, Including Dual-Payload Variations
Hangzhou DAC's DXC006 Data at ASCO Reinforce Conviction for CPT113, a Core Technology of Whitehawk's ADC Platform
Phase 1 Dose-Escalation Trials of HWK-007 and HWK-016 are Currently Enrolling; HWK-007 Trials-in-Progress Poster to be Presented at ASCO
MORRISTOWN, N.J., May 21, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced it entered into